Genetically modified filamentous phage as bactericidal agents: a pilot study
Article first published online: 8 SEP 2003
Letters in Applied Microbiology
Volume 37, Issue 4, pages 318–323, October 2003
How to Cite
Hagens, S. and Bläsi, U. (2003), Genetically modified filamentous phage as bactericidal agents: a pilot study. Letters in Applied Microbiology, 37: 318–323. doi: 10.1046/j.1472-765X.2003.01400.x
- Issue published online: 8 SEP 2003
- Article first published online: 8 SEP 2003
- 2003/0288: received 7 April 2003, revised 26 June 2003 and accepted 11 July 2003
- bacteriophage therapy;
Aims: To evaluate the ability of a filamentous phage encoding lethal proteins to kill bacteria without host-cell lysis.
Methods and Results: Bacterial survival was determined after infection of a growing Escherichia coli culture with phage M13 encoding either the restriction endonuclease BglII gene or modified phage λS holin genes. The genetically engineered phage exerted a high killing efficiency while leaving the cells structurally intact. When compared with a lytic phage, the release of endotoxin was minimized after infection with the genetically modified phages.
Conclusions: Genetically engineered phage can be used for efficient killing, concomitantly minimizing endotoxin release.
Significance and Impact of the Study: This feasibility study provides a possible strategy for the use of genetically engineered phage as bactericidal agents by optimizing the advantages and minimizing potential risks such as release of pyrogenic cell wall components.